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Postmenopausal females continue to smoke despite considerable health risks related to low 
levels of estrogen in combination with antiestrogenic effects of nicotine. These females face 
barriers to cessation that are more severe than their male and pre-menopausal counterparts. 
These barriers include negative affect, weight concerns, and menopausal symptom severity. 
Brief motivation-based interventions (B-MIs) that incorporate individualized health-related 
feedback have demonstrated efficacy for smoking cessation, but have not been tested among 
postmenopausal females. The current study explored the effect of negative affect, weight 
concerns, and menopausal symptom severity on motivation and readiness to quit smoking, and 
the effectiveness of a B-MI to increase motivation and readiness to quit, among 
postmenopausal females. Eighteen postmenopausal smokers were randomized to receive B-MI 
(n=8) or control treatment (n=10). Participants completed measures of negative affect, weight 
concerns, and menopausal symptoms, as well as measures of motivation, readiness and self-
efficacy to quit at pre- and post-treatment. Motivation and readiness to quit were reassessed 
one week following treatment, to test the stability of treatment effects. At baseline, weight 
concerns, specifically surrounding smoking to prevent overeating, were identified as related to 
increased motivation to quit smoking. Menopausal symptoms severity, specifically somatic 
symptoms, assessed at baseline, was associated with increased readiness for cessation. B-MI 
did not increase motivation, readiness or self-efficacy to quit; however, results indicate that 
motivation and readiness to quit increased over time and cigarettes per day decreased from 
baseline to follow-up by approximately 20-30%, despite no treatment group differences 
observed. These results provide valuable insight into enhancing engagement in a cessation 
treatment among this population. Future research recommendations are discussed.
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INTRODUCTION 
Cigarette smoking is the leading cause of preventable death in the United States, with 
more than 480,000 deaths resulting from cigarette smoking each year (Centers for Disease 
Control and Prevention [CDC], 2012; United States Department of Health & Human Services 
[USDHHS], 2014; USDHHS, 2010). Cigarette smoking is associated with an increased risk of 
cardiovascular disease, stroke and lung cancer, as well as diminished overall health. Among 
smokers, females have higher rates of serious smoking-related illnesses (i.e., myocardial 
infractions, lung cancer; Perkins, 2001; USDHHS, 2014). Despite the fact that the risk of dying 
from tobacco use has increased over the past 50 years, approximately 40 million adults (14.8% 
of all females) in the United States continue to smoke (CDC, 2015). Female smokers continue 
to use cigarettes for longer periods of time and have poorer treatment outcome rates when 
compared to male counterparts (CDC, 2012; Cepeda-Benito, Reynoso, & Erath, 2004; Perkins, 
2001). Overall, females have more difficulty quitting smoking than men, despite equal levels 
of motivation to quit and increased likelihood of seeking assistance for a quit attempt (Perkins, 
2001). 
Recent data suggests that cigarette smoking remains relatively common among older 
females, with 16.8% of 45 to 64-year-old women reporting current cigarette smoking and 7.5% 
of females 65 years old or older identify as current smokers (CDC, 2015). Many of these 
females are less willing to quit smoking as they increase in age (Breitling, Rothernbacher, 
Stegmaier, Raum, & Brenner, 2009). The smoking rate among older females is especially 
problematic given that nicotine is associated with lower levels of biologically active estrogen 
(Mueck & Seeger, 2005). Among females in menopause, this antiestrogenic effect has been 
reported to contribute to and even exacerbate adverse health effects, including increased risk of 
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cardiovascular disease, cancer and osteoporosis (Tanko ́ & Christiansen, 2004). Several studies 
have proposed additional barriers to successful quit attempts among older female smokers 
when compared to male and pre-menopausal female counterparts. These include increasing 
changes in affect and being more prone to weight gain, as well as experiencing more severe 
menopausal symptoms (McVay & Copeland, 2011). Based on these findings, it is clear that 
interventions are needed to reduce these barriers and increase motivation to quit smoking in 
postmenopausal females. 
 Motivational Interviewing (MI; Miller & Rollnick, 2013) is a style of communication 
used to help individuals resolve ambivalence towards changing behavior. MI has demonstrated 
efficacy to treat a variety of substance use disorders, including smoking cessation (Hettema & 
Hendricks, 2010). Brief MI-based interventions (B-MIs), which incorporate the style and 
techniques of MI and include assessment of an individual’s behavior, have proven to be 
effective methods to increase motivation to quit smoking among females (Curry, Ludman, 
Granham, Stoute, Grothaus, & Lozano, 2003; Dunn, Deroo, & Rivaria, 2001; Glasgow, 
Whitlock, Eakin, & Lichtenstein, 2000; Miller, Zweben, DiClemente, & Rychtarik, 1992; 
Whitlock, Vogt, Hollis, & Lichtenstein, 1997). Additionally, research suggests that many older 
smokers are motivated to quit due to smoking-related illnesses (Ockene, 1987). Thus, it may 
prove to be advantageous to explore the unique factors affecting motivation to quit smoking 
among postmenopausal female smokers and whether an established B-MI, which includes 
individualized smoking-related health feedback, will increase motivation to quit smoking 





Menopause is the cessation of menses, typically occurring at approximately 51 years 
old. It is the result of a depletion of ovarian primordial follicles, which eventually leads to 
insufficient estrogen available to regulate the menstrual cycle (Jensvold, 1996; Lobo, 2009; 
Sherwin, 1996). However, it should be noted that menopause occurs gradually, in phases, over 
a 10-year period, beginning when a female is approximately 40 years old (Jensvold, 1996). 
Conventional menopause is frequently divided into two phases, perimenopause (also 
encompassing the menopausal transition) and postmenopause (Lobo, 2009). The beginning of 
perimenopause occurs when the menstrual cycle becomes irregular, with variable cycle length 
and periods of amenorrhea (Burger, Hale, Robertson, & Dennerstein, 2007; Lobo, 2009).  
Significant endocrine changes occur during perimenopause. Inhibin B and 
antimullerian hormone begins to decrease as follicle numbers in the ovary decline with older 
age. As the follicles are less responsive to follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH), there is a decrease in secreted estradiol (E2). The low levels of E2 result in an 
increase in FSH to levels greater than 25 IU/L. It should be noted that these endocrine changes 
do not occur in a linear pattern and levels of hormones fluctuate throughout perimenopause 
(Burger et al., 2007; Hale, Zhao, Hughes, Burger, Roberston, & Fraser, 2007; Kimball, 1993; 
Lobo, 2009; Soule, Sherman, Parrott, Rebar, Santoro, Utian, & Woods, 2001). Vasomotor 
symptoms, as a result of these endocrine changes, occur in approximately 85% of 
perimenopausal women and continue for up to 5 years following amenorrhea (Israel & 
Youngkin, 1997). These symptoms include vasomotor, vaginal dryness, sleep disturbance, 
dysphoric mood, pain, and urinary and sexual symptoms, among other symptoms (McVay & 
Copeland, 2011; Woods & Mitchell, 2005). These symptoms are not specific to 
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perimenopause, as they can be experienced throughout the menopause phases (Woods & 
Mitchell, 2005).   
Following one year of amenorrhea, individuals are typically classified as 
postmenopausal. Postmenopause is defined by markedly low levels of E2, due to rising levels 
of FSH, which continue to rise for approximately two years. Additionally, there are decreases 
in levels of progesterone and undetectable levels of inhibin B and antimullerian hormone 
(Burger et al., 2007; Hale et al., 2007; Kimball, 1994; Lobo, 2009; Soule et al., 2001). The 
stabilization of the high FSH and low E2 levels occurs approximately 3 to 6 years following 
amenorrhea. During postmenopause, vasomotor symptoms, especially vaginal dryness and 
urogenital atrophy are commonly reported (Soule et al., 2001). Also, postmenopausal women 
have an increased risk for cardiovascular disease (CVD), bone loss/osteoporosis, and urinary 
incontinence (National Institute on Aging, 2015).  
Postmenopause and Smoking Cessation 
   Postmenopausal smokers are at increased risk for the adverse health effects related to 
menopause (i.e., cardiovascular disease, cancer, and osteoporosis; Tanko ́ & Christiansen, 
2004). Previous research has attributed this increase in health consequences to the 
antiestrogenic properties of smoking cigarettes. Cigarette smoking has been associated with 
increased hepatic estrogen metabolism and decreased serum estrogen levels, which exacerbate 
negative health outcomes, related to menopause and even attenuate protective effects of 
hormone therapies (Michnovicz, Hershcopf, Naganuma, Bradlow & Fishman, 1986; Tanko ́ & 
Christensen 2004). Furthermore, previous research has shown that female smokers enter 
menopause 1.8 years earlier than non-smoking counterparts, with mixed evidence that smoking 
history or quantity of cigarettes smoked may affect early menopause (McKinaly, Brambilla & 
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Posner, 1992; Parente, Faerstein, Celeste, & Werneck, 2008). Beginning the menopausal 
transition earlier is especially problematic as it is associated with increased and worsened 
health consequences (McVay & Copeland, 2011). 
Given the exacerbated health effects of smoking, greater efforts to promote smoking 
cessation are necessary for this population. Despite the need for effective treatments for 
postmenopausal smokers, no study to date has directly compared cessation outcomes among 
premenopause, perimenopause, and postmenopausal smokers. One study examined the 
effectiveness of transdermal nicotine replacement in 152 postmenopausal smokers. Participants 
receiving a 21-mg nicotine patch were more likely to remain abstinent at 1, 2, 6 and 12-week 
follow-ups then compared to individuals receiving a placebo transdermal patch. Among these 
participants, those endorsing a history of depression were less likely to have abstained at 
follow-up, and hormone therapy (HT) did not moderate outcomes (Oncken, Cooney, Feinn, 
Lando, & Kranzler, 2007).   
Additionally, when controlling for HT among postmenopausal smokers during a quit 
attempt, change scores of withdrawal, craving and primary intention to smoke were lower 
among females receiving a transdermal nicotine patch than those not receiving the active 
treatment (Allen, Hatsukami, Bade, & Center, 2004). Nicotine replacement therapy (NRT) is 
less effective among female smokers (Cepeda-Benito et al., 2004; Perkins, Conklin, & Levine, 
2008). Given the evidence that NRT is less effective among female smokers, the fact that NRT 
seemed effective among postmenopausal smokers is promising.  
Previous research demonstrates that females taking estrogen-based, hormonal 
contraceptives have faster nicotine metabolism and receive decreased positive reinforcement 
from nicotine (Benowitz et al., 2006; Dreher, Schmidt, Kohn, Furman, Rubinow, & Berman, 
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2007). This suggests that estrogen may accelerate nicotine metabolism while simultaneously 
decreasing its reward. Thus, females in postmenopause, when estrogen levels are low and more 
stable, are in a potentially advantageous position to make a cessation attempt (Benowitz, 
Lessovschlaggar, Swan, & Jacob, 2006; Benowitz, 2009;	Franklin, Ehrman, Lynch, Sciortino, 
O'Brien, & Childress, 2008).  These results provide preliminary evidence that postmenopause 
may be a particularly opportune time for a female to make a quit attempt (McVay & Copeland, 
2011). 
Despite this hypothesis, the smoking rates remain relatively high among older females 
(ages 45-65 years old), suggesting that there may be additional barriers for these women, 
which negatively affect their ability to quit smoking (CDC, 2015). Research to date has 
focused on the impact of diminishing levels of estrogen and the effectiveness of HT to 
influence smoking cessation outcomes and nicotine withdrawal symptoms, most notably mood, 
appetite, and weight changes related to perimenopause and postmenopause (Copeland, Waldo, 
Peltier, & Hecht, 2015). However, these collective empirical studies have provided mixed 
evidence to suggest that HT impacts these variables or smoking cessation outcomes and few 
consistent conclusions can be drawn regarding the impact of negative affect, weight concerns 
and postmenopausal symptoms severity (Copeland, Peltier, & Geiselman, 2016; Copeland et 
al., 2015). This highlights the need to further explore the potential barriers to cessation, which 
may be negatively affecting postmenopausal smokers’ quit attempts.  
Negative Affect 
An increase in negative affect, most notably depressive symptoms, is associated with a 
decrease in estrogen levels during and following menopause. For example, 221 females 
participated in a community-based study of menopausal symptoms, where they attended study 
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visits both during the perimenopause and postmenopause phases. Participants were two to four 
times more likely to experience a major depressive episode when they were in perimenopause 
or postmenopause, as opposed to when they were premenopausal (Bromberger, Kravitz, 
Change, Cyranowski, Brown, & Matthews, 2011). Furthermore, a cross-sectional study 
demonstrated that 24.7% of postmenopausal females in Turkey endorsed current levels of 
depression, as measured by the Beck Depression Inventory (Turkish Version; Unsal, Tozun, & 
Ayranci, 2011). These results indicate that a substantial number of postmenopausal females 
experience depression following the menopausal transition.  
There is strong evidence that negative affect impacts smoking cessation efforts for 
female smokers. Among female smokers, 33.6% of current daily smokers meet diagnostic 
criteria for a current major depressive episode and many females report a depressed mood 
following nicotine abstinence (Allen, Hatsukami, & Christianson, 2003; Husky, Mazure, 
Paliwal, & McKee, 2008). It is likely that this increased negative affect is exacerbated among 
postmenopausal female smokers during a quit attempt. The monoamine oxidase inhibiting 
(MAOI) content of cigarette smoke has historically been connected with antidepressant effects 
of cigarette smoking and increases in MAO-A distribution correlate with declining levels of 
estrogen. This indicates that antidepressant effects of cigarette smoking are heightened during 
perimenopause and postmenopause and may further complicate quit attempts (Copeland et al., 
2015). Furthermore, given that many women endorse symptoms of negative affect (i.e., 
depression, irritability, nervousness) during perimenopause and postmenopause, it has been 
proposed that a variety of factors, including vasomotor symptoms, sleep difficulties, and 
lifestyle/social factors may contribute to elevated levels of negative affect in this population 
(McVay & Copeland, 2011).   
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It has been suggested that HT may reduce negative affect among postmenopausal 
females making a quit attempt. However, current evidence demonstrates mixed results, with 
studies showing that taking HT during a cessation attempt both improves and worsens mood 
(Allen et al., 2003; Allen et al., 2004b). To date, there are no studies that directly explore the 
role of negative affect and motivation to quit smoking among this population, suggesting that 
further research is needed to establish the relationships among negative affect and smoking 
cessation, and motivation to quit smoking. 
Weight Concerns 
Weight gain is a common effect of smoking cessation and data demonstrates that 
women are more likely than men to have concerns about weight gain during a quit attempt 
(Perkins et al., 2008). Additionally, female smokers gain more weight than their male 
counterparts when quitting smoking. Williamson and colleagues (1991) reported that among 
those making a cessation attempt within a cohort of smokers, males gained 2.8kg, and females 
gained 3.8kg. Additionally, 13.4% of females who quit smoking gained greater than 13kg 
(Williamson, Madans, Anda, Kleinman, Giovino, & Byers, 1991). Further research indicates 
that approximately 19% of females who quit smoking gained more than 20% of their body 
weight (O’Hara, Connett, Lee, Nides, Murrary, & Wise, 1998). This weight gain is problematic 
as women may be more likely to relapse due to post-cessation weight gain when attempting to 
quit smoking (Swan, Ward, Jack, & Carmelli, 1993).  
Weight gain during a quit attempt is further compounded during perimenopause and 
postmenopause, as many women gain weight and increase body fat during this time. One study 
cited an average weight gain of 2.3 kg over a 3-year period with 20% of participants gaining 
4.5 kg or more (Wing, Matthews, Kuller, Neilahn, & Plantinga, 1991). Among postmenopausal 
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female smokers on HT, those who abstained from smoking for two weeks gained 1.28 kg, 
while non-abstainers lost 0.54kg (Allen, Brintnell, Hatsukami, & Reich, 2004). Additionally, 
those abstaining from smoking reported an increase in total kilocalorie and carbohydrate 
consumption during the 2-week period of abstinence (Allen et al., 2004a).  
The concern about gaining weight when quitting smoking has been identified as an 
obstacle to a successful quit attempt across populations and has been proposed as a reason 
female smokers drop out of cessation programs (Copeland, Martin, Geiselman, Rash, & 
Kendzor, 2006; McVay & Copeland, 2011). Among female smokers, 39% of older women 
(over 40 years old) were unwilling to gain any weight if they quit smoking (Pomerleau & 
Kurth, 1996). Postmenopausal females report being less positive about their appearance than 
premenopausal females. However surprisingly, the importance of positive body shape and 
weight decrease with age (Tiggemann, 2004). Research has demonstrated that despite high 
levels of smoking-related weight concerns among postmenopausal females, these individuals 
are more likely to enter treatment than pre-menopausal women with elevated levels of 
smoking-related weight concerns. It has been hypothesized that this may be associated with an 
increase in health concerns or more experience with past quit attempts, especially given the 
decrease in importance of positive body shape and weight decrease (Copeland et al., 2006; 
Tiggemann, 2004). Thus far, no studies directly explore the role of weight gain concerns and 
motivation to for smoking cessation among this population. Further research is needed to 
establish the relationship between weight concerns and motivation to quit smoking. 
Menopausal Symptoms 
The antiestrogenic effect of cigarette smoking has been shown to increase the 
symptomatology associated with menopause (McVay & Copeland, 2011). For instance, in a 
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recent survey, Whiteman and colleagues (2003) found that 56% of females between 40-60 
years old endorsed moderate to severe hot flashes, with smokers reporting an increased risk of 
hot flashes. Furthermore, among current smokers, those with a more significant smoking 
history (i.e., greater amount smoked) had an increased risk for hot flashes (Whiteman, 
Staropoli, Langenberg, McCarter, Kjerulff, & Flaws, 2003). These findings support previous 
research establishing that smokers report more severe and more frequent hot flashes (Staropoli, 
Flaws, Bush, & Moulton, 1998).   
Cigarette smoking among postmenopausal females has also been associated with 
increased vaginal atrophy when compared to non-smoking counterparts (Kalogeraki et al., 
1996). Copeland and colleagues (2016) assessed the severity of menopausal symptoms among 
postmenopausal females following a quit attempt. Among participants, smokers reported 
significantly greater reports of tingling, fatigue, and muscle aches, when compared to 
postmenopausal females who had abstained for two weeks following the initial quit attempt 
(Copeland et al., 2016). While research has established a connection between menopausal 
symptoms, including vasomotor symptoms, and cigarette smoking, no research to date has 
explored the effect these menopausal symptoms (i.e., hot flashes, sweating, vaginal atrophy, 
etc.) have on motivation to quit smoking. It is possible that more frequent or more severe 
menopausal symptoms would be associated with less motivation to quit smoking, as greater 
reports of menopausal symptoms have been related to decreased rates of abstinence (Copeland 
et al., 2016). 
Motivational Interviewing 
William Miller pioneered Motivational Interviewing (MI) in 1983 as a 
psychotherapeutic intervention for substance use disorders. MI is a client-centered, directive 
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communication style that helps individuals explore and resolve ambivalence to positive 
behavioral change (Miller, 1983; Miller & Rose, 2009). Since its original development, MI has 
established itself as an efficacious treatment which helps increase one’s intrinsic motivation, 
resolve ambivalence and commit to making a behavioral change (Dunn et al., 2001; Miller & 
Rose, 2009; Madson, Schumacher, Baer, & Martino, 2016).  
MI Theoretical framework 
MI’s theoretical underpinnings are grounded in several psychological theories. 
Cognitive dissonance, initially framed by Leon Festiger, is the recognition that one’s actions 
are inconsistent with one’s beliefs. This recognition is theorized to motivate an individual to 
solve this discrepancy through the change of beliefs and/or behaviors (Festiger, 1957). MI 
conceptualizes cognitive dissonance as a vital motivational factor in developing a gap between 
status quo and positive behavioral change. MI theory asserts that behavioral change occurs 
when an individual recognizes such a discrepancy between one’s values and/or goals and his or 
her current status quo, although this difference should not be so large that it demoralizes an 
individual (Miller & Rollnick, 2013). It has been theorized that, in accordance with the theory 
of self-perception, allowing an individual to defend the logic underlying a behavioral change, 
will increase one’s commitment to such change (Bem, 1972; Hettema, Steele & Miller, 2005; 
Miller & Rose, 2009). Thus, MI dialogue strives to foster language that argues for change, also 
known as “change talk,” as increases in discussion of change often predicts one’s commitment 
to change (Miller & Rollnick, 2013; Miller & Rose, 2009). To support such “change talk” and 
subsequent behavioral changes, implementation of a supportive and nonjudgmental context is 
required (Miller & Rose, 2009). MI draws from Carl Roger’s theory of “necessary and 
sufficient” interpersonal conditions, which is thought to be required to explore and resolve 
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ambivalence while developing discrepancy (Miller & Rollnick, 2013; Miller & Rose, 2009; 
Rogers, 1959). Overall, the inclusion and development of these theories has advanced MI to be 
an efficacious intervention, through its collaborative conversation style and exploration of 
values and motivations, which foster positive behavioral change (Hetteman et al., 2005; Miller 
& Rollnick, 1992; Miller & Rollnick, 2002; Miller & Rollnick; 2013). 
MI Processes, Strategies, Skills and Principles 
In order to identify and resolve ambivalence towards a behavioral change, MI includes 
four processes: engaging, focusing, evoking and planning.  The foundation of a MI 
conversation is engaging the patient in a collaborative relationship. This begins to foster a 
cooperative and supportive context, which allows an individual to feel comfortable and 
actively participate in the MI-based conversation. Initially, the clinician and participant engage 
in focusing, to clarify the goal that will be worked towards within the MI discussion. This 
ensures that the MI-based conversation will be a goal-directed discussion, in which 
ambivalence is explored and countered constructively. A successful MI-based discussion will 
lead to evoking behavioral change and fostering an individual’s intrinsic motivation for change, 
through eliciting and responding to “change talk.” The culmination of these above-mentioned 
processes results in planning, in which one makes a specific plan for positive behavioral 
change and assesses one’s intention to implement the plan (Miller & Rollnick, 2013). These 
processes are implemented in discussion through the use of a variety of MI-based strategies, 
including reflective listening (accurate empathy), eliciting motivational statements, examining 
ambivalence, and reducing resistance (Dunn et al., 2001; Rubak, Sanbaek, Lauritzen & 
Christensen, 2005).     
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 MI also employs basic principles in addition to these processes and strategies to help an 
individual work towards a behavioral change. These principles include: expressing empathy, 
developing discrepancy, responding to sustain talk, and supporting self-efficacy (Miller & 
Rollnick, 2013; Miller & Rollnick, 2002). Expressing empathy describes a clinician’s accurate 
understanding of the individual’s status quo and values, communicated through reflective 
listening techniques. Expressing empathy is the communication of accurate empathy, which 
allows the clinician to understand the patient’s perspective and ambivalence towards change in 
a non-judgment and supportive context that is congruent with the MI processes (Burke, 
Arkowtiz, & Menchola, 2003; Miller & Rollnick, 2013). Within this regard, MI encourages the 
expression of empathy to allow the patient the environment to explore and reflect on one’s 
values and goals (Miller & Rollnick, 2013).  
 MI strives to have an individual identify one’s values and goals, while also assessing 
how the current behavior supports or discourages said values and goals. This development of 
discrepancy is the fundamental goal of MI, as it emphasizes the importance of behavioral 
change. Framed within the context of cognitive dissonance, MI helps an individual develop 
discrepancy between the status quo and desired behavioral change (Festinger, 1957; Miller & 
Rollnick, 2013). Through MI-based skills and strategies, such as selective reflection and open-
ended questions, an individual will develop a discrepancy between one’s current behaviors and 
overall values (Burke et al., 2003). Engagement in the MI-based conversation will give an 
individual the opportunity to voice reasons for and against change, thus building one’s intrinsic 
motivation to make a behavioral change (Miller & Rollnick, 2013). Through articulating and 
resolving this discrepancy, an individual will increase his or her commitment to making the 
stated behavioral change (Bem, 1972; Miller & Rollnick, 2013).   
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 During the exploration of ambivalence, it is common for individuals to minimize the 
need to make the targeted change. Commonly referred to as sustain talk, this further reveals 
one’s ambivalence and is a normal and expected part of change (Burke et al., 2003; Miller & 
Rollnick, 2013). Miller and Rollnick (2013) advise that it is necessary to accept such sustain 
talk as reflections of ambivalence and utilize skills of reflective listening, emphasis of 
autonomy and reframe this opposed perspective. Such response is theorized to help empower 
the individual to problem solve and develop novel solutions to the disagreement, through 
change talk (Miller & Rollnick, 2013).  
 Through the processes of MI, the individual establishes both an understanding of the 
importance of the behavioral change and begins to develop the confidence to change one’s 
status quo (Burke et al., 2003). For behavioral change to occur, it is essential for the individual 
to develop confidence, known also self-efficacy, in one’s ability to make the behavioral change 
(Miller & Rollnick, 2013). Self-efficacy is one’s belief that goals that one sets for oneself are 
achievable (Bandura, 1977). This belief in one’s ability to achieve and maintain behavioral 
goals is a reasonable predictor of treatment outcomes (Miller & Rollnick 2002). Bandura’s 
proposed theory of self-efficacy postulates that an individual estimates his or her efficacy 
expectation, which is the belief that one is able to complete a given task to accomplish the set 
goal. These efficacy expectations determine the amount of effort and one will put forth to 
accomplish the set goal. The stronger one’s self-efficacy the more effort an individual will 
demonstrate (Bandura, 1977). Thus, improving self-efficacy requires the fostering of hope that 
the behavioral change is possible and developing the confidence that one is able to accomplish 
the set behavior. If there is no hope or confidence to change, it is likely that no change will 
occur (Miller & Rollnick, 2013).  
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 It has been proposed that self-efficacy may be one of the mediating factors of MI 
enacting change (Miller & Rollnick, 2013). MI enhances self-efficacy through its 
collaborative, supportive nature, fostering of autonomy and evocation of intrinsic motivation to 
accomplish the targeted behavioral change (Miller & Rollnick, 2013; Miller & Rollnick, 2002). 
It is thought that through these principles, MI helps evoke and strengthen hope already present 
in the individual (Miller & Rollnick, 2013). Miller & Rollnick propose that the use of 
techniques, including providing information/advice, identifying/affirming strengths, reviewing 
past successes, and reframing fosters this hope, builds confidence talk and thus increases the 
likelihood of a behavioral change (Miller & Rollnick, 2013). 
 MI is frequently adapted into interventions to foster specific behavioral changes, 
including smoking cessation (Heckman, Egleston, & Hofmann, 2010). These MI-based 
interventions assert that the responsibility and capability for behavioral change are within the 
individual. The treatment strives to create an environment in which an individual’s motivation 
and commitment to change will be enhanced and strengthened. To accomplish this, MI 
interventions often include personalized feedback presented to the individual in a structured 
manner. This feedback allows he or she to compare one's personal results to normative ranges 
while also focusing on developing action plans for the targeted change (Finney, Wilbourne & 
Moos, 2007; Miller et al., 1992). These interventions allow the clinician to provide 
psychoeducational information and feedback to the individual, in an MI-consistent manner. 
Thus, the clinician explores the individual’s prior knowledge and assesses interest in the 
behavior change. It is recommended that the clinician shares information regarding the 
assessment and then utilizes open-ended questions to explore the individual’s personal 
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responses. Doing so will elicit the individual’s interpretations and concerns, thus increasing 
commitment to the behavioral change (Miller & Rollnick, 2013; Miller & Sanchez, 1993). 
 Miller and Sanchez (1993) provide a list of “active ingredients,” of empirically 
supported brief MI-based interventions (B-MI). These components include feedback regarding 
substance use risk, emphasis on personal responsibility for the proposed change and advice for 
the change. Additionally, detailing a “menu” of alternative change options, emphasis on 
empathy and promotion of the individual’s self-efficacy have been shown to be successful in 
fostering behavior change (Miller & Sanchez, 1993). These ingredients are found in numerous 
brief interventions, and substantial evidence suggests that these low-cost B-MIs are effective 
for increasing motivation among a range of substance use disorders (Finney et al., 2007). 
However, it should be noted that a common critique of B-MIs is that it has a rapid impact, but 
the effect gradually decreases across time (Hettema, et al., 2005). One meta-analysis 
demonstrated that effect sides for short-term follow-up decreased from 0.77 to 0.30 one year 
later and another meta-analysis indicated the benefits of MI decreased as follow-up times 
increased (Hettema et al., 2005; Lundahl, Kunz, Browness, Tollefson, & Burke, 2010). It has 
been hypothesized that this decrease in effect size is at least in part observed due to control or 
comparison treatments “catching up” over time, as seen with pharmacological or medical 
interventions. Further, the observed effect is diminished when the MI preludes another 
treatment, which increases its efficacy and the length of its effect (Hettema, et al., 2005).  
MIs and Smoking Cessation 
 MI-based interventions (including B-MIs) have been proved to be effective 
interventions for smoking cessation among varying populations and health care settings (Lai, 
Cahill, Qin, & Tang, 2011). A meta-analysis, including 14 randomized control trials (RCTs), 
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demonstrated the MI-based treatments resulted in a significant effect on the nicotine 
abstinence, when compared to brief advice or treatment as usual. Effect sizes of these RCTs, 
included in the meta-analysis, ranged from 1.22-3.49 (Lai et al., 2011). Further, another meta-
analysis indicated that smokers (82% female) receiving MI-based interventions were 45% 
more likely to be nicotine abstinence at follow-up than the control groups (Heckman et al., 
2010).  Among a population of female smokers, MI interventions outperformed other treatment 
conditions at long-term follow-up time points (Hettema & Hendricks, 2010).  
B-MIs for smoking cessation have increased quit attempts, reduced number of 
cigarettes smoked per day and greater motivation to quit in a variety of treatment settings and 
populations (Colby, et al., 1998; Curry et al., 2003; Glasgow et al., 2000; Harris, Catley, Good, 
Cronk, Harrar & Williams, 2010; Manuel, Lum, Hengl & Sorensen, 2013). For instance, 
among undergraduate student smokers, receiving four, 20-30 minute sessions of MI for 
smoking cessation, a reduction in the number of days smoked and the number of cigarettes 
smoked per day through a 30-day period were observed (Harris et al., 2010). Additionally, a 
single session MI decreased the mean number of cigarettes smoked per day when compared to 
an advice-only group among HIV+ female smokers (Manuel et al., 2013). It should be noted 
that no increase in effectiveness has been observed when patients receive more than a single 
session of MI or multiple sessions in both smoking cessation treatments and other 
interventions, including alcohol-based interventions (Kulesza, Apperson, Larimer & Copeland, 
2010; Lai et al., 2011). A single MI session for smoking cessation appears sufficient to produce 
positive treatment effects.  
According to relapse models described in the literature to date, self-efficacy has been 
identified as a key component to enhance positive behavioral changes and treatment outcomes, 
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including modestly predicting cessation outcomes among smokers (Gwaltney, Metrik, Kahler, 
& Shiffman, 2009). Research has demonstrated that individuals who abstain from smoking 
during a quit attempt report a higher level of baseline self-efficacy than those who did not have 
a successful cessation attempt (Gwaltney et al., 2009).  Given that female smokers often report 
lower rates of self-efficacy to make a question attempts, it seems as though fostering self-
confidence will be an important factor in a successful cessation attempt (Perkins, 2001). 
Previous research among female smokers has demonstrated that in a path analysis, smoking 
cessation interventions have an effect on readiness to quit, which subsequently increases self-
efficacy, further enhancing readiness to quit (Warnecke et al., 2001). In light of the relationship 
between self-efficacy and readiness to quit smoking, it is likely advantageous to foster an 
individual’s self-efficacy to quit smoking when attempts to build motivation and readiness for 
cessation. 
Despite lower rates of self-efficacy to make a successful cessation attempt among 
female smokers, B-MIs are effective in both male and female smokers (Dunn et al., 2001; 
Perkins, 2001; Whitlock, et al., 1997). In fact, women have even demonstrated long-term 
cessation success when using a B-MI. Among low-income female adult smokers in a pediatric-
based clinic, a greater number reported nicotine- abstinence when compared to treatment as 
usual at both a 3-month and 12-month follow-up (7.7% vs. 3.4% and 13.5% vs. 6.9%, 
respectively; Curry et al., 2003). Additionally, Ruger and colleagues (2008) reported that 
among low-income pregnant smokers, MI helped prevent relapse when compared to usual care 
(Ruger, Weinstein, Hammond, Kearney, & Emmons, 2008).  
The promising findings among female smokers’ response to MIs also extend to 
increasing motivation to quit smoking among those not wanting to stop smoking (i.e., 
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precontemplation/ contemplation stages of the Stages of Change algorithm; Haug, Svikis & 
DiClemente, 2004; Stotts, DiClemente, & Dolan-Mullen, 2002). For instance, following four 
study sessions, there was a significant difference in motivation to quit smoking among 
methadone-maintained pregnant females receiving a MI (with personalized feedback) than 
those receiving usual care. Those who received the MI were also more likely to have advanced 
to the next stage of change (i.e., moved from precontemplation to contemplation) than with 
usual care (35% vs. 15%; Haug et al., 2004).  
Overall, evidence suggests that MIs for smoking cessation are a promising treatment for 
increasing motivation among female smokers. Further MIs for smoking cessation may increase 
cessation rates among those female smokers making a quit attempt.  
Summary 
 Postmenopausal females are smoking at relatively high rates (CDC, 2015). This is 
concerning considering the increased health consequences associated with the synergistic 
effect of decreased levels of estrogen related to both menopausal and smoking status (Lobo, 
2009; Benowitz, 2006). Evidence suggests that low levels of estrogen may provide greater 
success during a quit attempt. However, limited research has explored the unique barriers that 
affect postmenopausal female smokers’ motivation and readiness to quit smoking (McVay & 
Copeland, 2011). Furthermore, evidence suggests that B-MIs (with smoking-related health 
feedback) may increase motivation to quit smoking among postmenopausal females (Haug et 





PURPOSES AND HYPOTHESES OF THE PRESENT STUDY 
Specific Aim 1 
  To determine the impact of negative affect, weight concerns, and menopausal 
symptoms on motivation and readiness to quit smoking among postmenopausal females. 
Hypothesis 1 
 Research to date has demonstrated that negative affect, weight concerns, and 
menopausal symptoms affect smoking behavior and cessation (McVay & Copeland, 2011). 
Thus, the current study tested the hypothesis that participants receiving higher scores on 
measures of negative affect, weight concern, and menopausal symptoms will report lower 
motivation and readiness to quit smoking at baseline (T1).    
Specific Aim 2 
 To determine the effects of a MI on motivation and readiness to quit smoking in 
postmenopausal females.  
Hypothesis 2 
Previous research has found that female smokers respond to B-MIs (Stotts et al., 2002; Haug et 
al., 2004). Given this evidence, it is plausible that B-MIs may increase motivation to quit 
smoking among postmenopausal females. Thus, the present study tested the hypothesis that 
participants receiving the B-MI will report an increase in motivation and readiness to quit 







In order to verify the stability of this B-MI, the present study tested the hypothesis that 
participants receiving the B-MI will report higher levels of motivation and readiness to quit at 
1-week follow-up (T3) as compared to individuals in the control condition.   
Specific Aim 3 
 To determine the impact of a B-MI on self-efficacy to quit smoking. 
Hypothesis 4 
It has been asserted that MI-based interventions increase self-efficacy (Miller & Rollnick 
2013). Thus, the present study tested the hypothesis that participants receiving the B-MI will 
report an increase in self-efficacy to quit smoking from baseline (T1) to post-intervention (T2) 
when compared to participants in the control condition. 
Hypothesis 5 
To verify the stability of this B-MI to increase self-efficacy to quit over time. The current study 
tested the hypothesis that participants receiving the B-MI will report higher levels of self-
efficacy to quit at 1-week follow- up (T3) as compared to individuals in the control condition.   
METHOD 
Participants 
 Participants included members of the Baton Rouge community who were recruited 
through advertisements (print and Internet) and fliers posted on the campus of Louisiana State 
University (LSU) and the surrounding community, as well as through the local libraries, 
churches and bingo halls. All advertisement materials were tailored to recruit nicotine-
dependent participants. Inclusion criteria included female participants over the age of 40 years 
old, who self-reported cessation of menses for at least one year. Participants were required to 
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smoke at least ten cigarettes/day, have a carbon monoxide (CO) level of > 10 ppm and an FSH 
screen of > 25 mIU/mL. Exclusion criteria included current menses within the past year.   
 Interested participants, who contacted the laboratory either by E-mail or telephone, as 
listed in advertisements, were called by the experimenter to complete a phone screening to 
determine study eligibility. Those participants who were eligible for the study were invited to 
the Psychological Services Center (PSC) on the campus of LSU to complete the study session. 
Ineligible participants were queried regarding interest in additional ongoing research in the 
laboratory and subsequently screened for inclusion/exclusion criteria for other research 
protocols. If not enrolled in an additional study, individuals were asked if they were interested 
in remaining on a contact list for future studies. Participants enrolled received $50 
compensation for completing the study. 
A total of 18 participants (8 in treatment group; 10 in control group) were recruited. 
This was less than the proposed 64 participants (32 in each group) needed to obtain an 
estimated large effect size (Cohen’s f = 0.40) with a power of .80 and alpha level of .05 
(calculated with G*power; Faul, Erdfelder, Lang  & Buchner, 2007; based on meta-analysis of 
short-term treatment follow-up, Hettema & Hendricks, 2010). All reasonable recruitment 
efforts were made to achieve the proposed sample size, including strategic placement of 
advertisements (i.e., community centers, coffee shops, bingo halls, and 12-step meeting 
locations) and allowing participants to refer friends; however similar to previous research 
involving female smokers with hormonal-based inclusion/exclusion criteria, conducted in 
similar clinical settings, this was not possible (McVay, 2011). Given that the sample size was 
smaller than anticipated, and therefore the power of significance tests reduced, effect sizes 
and/or confidence intervals for all groups were also calculated.  
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Measures 
Phone Screening (See Appendix A).  This screening consisted of questions to 
determine participant eligibility and assessed gender, age, daily smoking rate (i.e., number of 
cigarettes smoked per day), number of years smoked, and last menses. The phone screening 
was used in the present study to assess inclusion and exclusion criteria of potential participants 
before being enrolled in the current study. 
Demographic Questionnaire (See Appendix A). This questionnaire was administered 
to eligible participants upon attending the in-person visit. It consists of 12 items and assessed 
age, gender, race, relationship status, level of education, last reported menses, daily smoking 
rate, years smoked, preferred brand of cigarettes, and previous quit attempts. Additionally, the 
questionnaire assessed if the participant has undergone surgical menopause, or currently taking 
a hormonal therapy (HT), as well as the type of HT, if applicable. In the present study, the 
demographics questionnaire was used to assess differences in demographic data between 
treatment groups. 
Fagerström Test for Nicotine Dependence (FTND; Heatherton, Kozlowski, Frecker 
& Fagerström, 1991; see Appendix A). The FTND is a six-item questionnaire assessing for 
nicotine dependence. It evaluates the quantity of cigarette consumption, frequency of use and 
craving to smoke. Possible scores range from zero to ten, with a higher score suggesting 
greater dependence. The FTND score has been shown to correlate with physiological 
measurements, including pack years smoked and cotinine (Dijkstra & Tromp, 2002). High 
scores on the measure have been shown to correspond with more expected withdrawal 
symptoms and lower self-efficacy to quit (Etter, 2005; Etter, Duc, & Perneger, 1999; 
Pomerleau, Carton, Lutzke, Flessland, & Pomerleau, 1994).  The FTND was used in the 
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current study to assess the level of nicotine dependence, which was used to evaluate 
differences in severity of nicotine dependence between treatment groups. 
University of Rhode Island Change Assessment (URICA; DiClemente & Hughes, 
1990; McConnaughy, DiClemente, Prochaska, & Velicer, 1989; See Appendix A). The 
URICA is a 32 item, self-administered instrument designed to assess the readiness for 
behavioral change. The questionnaire is adapted from the categorical stages of change model to 
provide a continuous score for an individual’s readiness to quit a variety of behaviors (e.g., 
smoking, weight loss, alcohol use). Researchers can insert the behavior targeted for change 
into the instrument; the current study utilized applied the URICA to assess readiness to quit 
smoking (DiClemente & Hughes, 1990; DiClemente, Prochaska, Fairhurst, Velicer, Velasquez, 
& Rossi, 1991; Prochaska, DiClemente, & Norcross, 1992). The URICA includes four 
subscales (Precontemplation, Contemplation, Action, and Maintenance) and responses are 
given on a 5-point Likert scale ranging from 1 to 5 (“strongly disagree” to “strong 
agreement”). These scales are combined arithmetically into a composite score to assess 
changes in readiness to quit the designated behavior in response to treatment (Amodei & 
Lamb, 2003; DiClemente & Hughes, 1990). Originally developed as a generic assessment of 
readiness to the targeted behavior in psychotherapy, the URICA has been successfully adapted 
to assess readiness to engage in smoking cessation treatment, as well as other cessation-based 
psychotherapies. Its composite score has been shown to be sensitive to B-MIs for smoking 
cessation, as well as drug use, domestic violence, alcohol use (Amodei & Lamb, 2003; 
Levesque, Gelles, & Velicer, 2000; Soderstrom et al., 2007; Stephens, Celluccci, & Gregory, 
2004;). When adapted for smoking cessation, it is positively correlated with the traditional, 
categorical stages of change ladder (r =.42) and shows adequate concurrent and convergent 
 25 
validity with the stages of change ladder (Amodei & Lamb, 2003; Stephens et al., 2004). The 
composite score of the URICA was used to assess readiness to quit smoking in the present 
study. 
Motivation to Stop Scale (MTSS; Kotz, Brown, & West, 2013; See Appendix A). The 
MTSS is a single-item question, which asks current smokers to describe his/her current 
motivation to quit smoking. It includes a seven-point Likert scale, which ranges from 1 (“I 
don’t want to stop smoking”) to 7 (“I REALLY want to stop smoking and intend to in the next 
month.” MTSS scores have predicted quit attempts after a six-month follow-up in a linear 
fashion (Kotz et al., 2013). Further, the MTSS has demonstrated adequate accuracy in 
discriminating among smokers who did and did not quit smoking at follow-up (Area Under the 
Receiver Operating Characteristic [ROCAUD ]=0.67; Kotz et al., 2013). In the present study, the 
MTSS score was used to assess motivation to quit smoking. 
Smoking Self-Efficacy Questionnaire (SEQ-12; Etter, Bergman, Humair & Perneger, 
2000; see Appendix F). The SEQ-12 is a self-report measure used to assess an individual’s 
confidence to abstain from smoking when exposed to both external and internal stimuli. The 
measure includes two, six-item subscales which assess the individuals’ ability to refrain from 
smoking when facing both internal (Scale 1) and external (Scale 2) stimuli. Individuals respond 
to a 5-point Likert scale (ranging from “not at all sure” to “absolutely sure”). The SEQ-12 has 
demonstrated high internal consistency in the present study (“internal stimuli,” α = 0.92; 
“external stimuli,” α = 0.88) and similarly high test-retest correlation coefficients in previous 
research (r = 0.95; r = 0.93, respectively; Etter et al., 2000). The total score of the SEQ was 
used to assess self-efficacy to quit in the present study.   
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Positive and Negative Affect Schedule (PANAS; Watson et al., 1988; See Appendix 
A). The PANAS is a 20-item measure of affect designed to assess an individual’s positive and 
negative affect. It includes two, 10-item mood scales (Positive and Negative Affect Scales). 
Individuals rate items on a Likert scale from 1 (very slightly or not at all) to 5 (extremely). In 
the present study, the measure demonstrated good internal consistency for the positive affect 
and negative affect (α = 0.86; α’s = 0.86, respectively) and moderate concurrent validity in 
previous research (r’s = .51-.74; Watson et al., 1988). The negative affect scale was used in the 
present study to assess negative affect among postmenopausal smokers. 
Smoking-Related Weight and Eating Episodes Test (SWEET; Adams, Baillie, & 
Copeland, 2011; See Appendix A). The SWEET is a 10-item measure designed to assess an 
individual’s tendencies to smoke in response to body image concerns, as well control appetite 
and overeating. It includes four content domains (smoking to suppress appetite, smoking to 
prevent overeating, smoking to cope with body dissatisfaction, and withdrawal-related appetite 
increases). Individuals rate items on a 5-point Likert scale (ranging from 1 = never, 5 = 
always). The SWEET demonstrates excellent internal consistency (α = 0.88, in the present 
study), as well as validity in predicting smoking frequency, eating pathology, and body image 
concerns (p’s < 0.05; Adams et al., 2011). The SWEET total score was used in the present 
study to assess weight concerns related to smoking among postmenopausal smokers. 
Menopause Rating Scale (MRS; Hauser, Huber, Keller, Lauritzen, & Schneider, 1994; 
Heinemann et al., 2004; Potthoff, Heinemann, Schneider, Rosemeier, & Hauser GA, 2000; See 
Appendix A). The MRS is an 11-item measure designed to assess 11 symptoms of menopause. 
It asks respondents to rate symptoms across five severity categories (no symptom, mild, 
moderate, marked, and severe). The items are computed to calculate a total score, as well as 
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three subscales (psychological, somatic and urogenital). The measure demonstrates adequate 
internal consistency (α = 0.68) in the present study. Additionally, the measure is highly 
correlated with the Kupperman index (a numerical index of menopausal symptoms; r = 0.91; 
Schneider, Heinemann, Rosemeier, Potthoff, & Behre, 2000). The MRS total score was used in 
the present study to assess menopause symptoms severity among postmenopausal smokers. 
Geriatric Depression Scale- Short form (GDS; Sheikh & Yesavage, 1986; See 
Appendix A). The GDS is a 15-item measure of depressive symptoms in older adults. 
Individuals chose “yes” or “no” to a series of questions regarding how one has felt over the 
past week. Individuals who score 0-5 are considered “normal,” while scores of 6-8 are 
indicative of mild depression, 9-12 of moderate depression and 12-15 of severe depression. 
Previous research has indicated that the GDS had a sensitivity of 92% and specificity of 81% 
(Lyness, Noel, Cox, King, Conwell, & Caine, 1997). The GDS total score was used in the 
present study as a second measure of negative affect in postmenopausal smokers.  
Alcohol Use Disorders Identification Test—Self-Report Version (AUDIT; Babor, 
Higgins-Biddle, Saunders, & Monteiro, 2001; See Appendix A). The AUDIT is a 10-item 
screening instrument to detect excessive drinking patterns. The brief questionnaire contains 
questions assessing the amount and frequency of drinking, alcohol dependence and 
problematic drinking. Items are scored on a five-point Likert scale, with higher scores 
indicative of more problematic alcohol use. A cutoff score of eight has produced sensitivities 
generally in the mid 0.90’s, and specificities in the mid 0.80’s. Given the established 
relationship between alcohol consumption and tobacco use, the AUDIT was used to measure 
problematic drinking patterns in the present sample (Bobo & Husten, 2000; Grant, Hasin, 
Chou, Stinson, & Dawson, 2004).  
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Materials 
FSH Urine Test Cassette (BTNX Inc., Ottawa, Canada). The Rapid Response 
Menopause FSH (urine) Test Cassette is a non-invasive, qualitative method to aid in the 
detection of menopause. The cassette is a lateral flow immunoassay designed to detect urine 
FSH levels above 25 mlU/ml. Urinary FSH test cassettes are a reliable and valid method of 
detecting FSH levels, to evaluate the onset of menopause. The cassette detects FSH levels 
above 25 mlU/ml with 100% specificity and 99% accuracy; there is no cross-reaction with 
human chorionic gonadotropin (hCG), thyroid stimulating hormone (TSH), and luteinizing 
hormone (LH; BTNX Inc., 2015).   
The test is conducted by pipetting a urine specimen into the test cassette. The test can 
be interpreted after 3 minutes, with a positive result indicated by two lines in the test line 
window that are the same color or darker than the control line. It is recommended that the test 
is repeated one week after the initial test to confirm results due to the instability of FSH levels 
(BTNX Inc., 2015). In the present study, the FSH urine test cassette was used at T1 and T3 to 
assess the FSH levels and confirm that the participant was postmenopausal. 
Carbon Monoxide Level. The level of carbon monoxide was determined with the 
Vitalograph-BreathCO Monitor. This monitor is a non-invasive instrument used to measure the 
concentration of carbon monoxide, as displayed in parts per million, (ppm), within a single 
breath (Vitalograph Inc., Lenexa, KS). In the present study, the level of carbon monoxide 
served as biological confirmation of daily smoking. Additionally, it was used in the Health 
Effects of Smoking B-MI protocol (Copeland, 2015) as biofeedback information related to 
smoking behaviors.  
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Lung Age. (Vitalograph Inc., Lenexa, KS). Lung age was determined with the 
Vitalograph- Lung Age Indicator, which is a non-invasive instrument used to identify 
individuals in pre-symptomatic stage of chronic obstructive pulmonary disease (COPD; 
Vitalograph Inc., Lenexa, KS). The instrument compares an individual’s FEV1 reading, as 
based upon three breath samples, with predicted normative values to interpret one’s lung age. 
This reading can be utilized when illustrating the negative consequences of smoking on lung 
functioning.  In the present study, lung age was used in the Health Effects of Smoking B-MI 
protocol as biofeedback information related to smoking behaviors (Copeland, 2015). 
Blood Pressure and Heart Rate. Blood pressure and heart rate will be collected with 
the Walgreen Digital Blood Pressure Monitor HD 2000, which is a non-invasive instrument 
used to measure the	systolic and diastolic blood pressure, as well as heart rate measurements.  
In the present study blood pressure and heart rate measures was utilized in the Health Effects 
of Smoking B-MI protocol  as biofeedback information related to smoking behaviors 
(Copeland, 2015). 
Smart WeighTM Digital BMI Body Fat Weight Scale. The Smart WeighTM scale 
calculates BMI, body fat percentage, body water percentage, muscle mass and bone mass. The 
scale utilizes bioimpedance analysis technology, which sends a mild electrical current through 
its stainless steel bars on the platform. In the present study, body mass indices were controlled 
for between treatment groups. BMI is a measure of height and weight that is a commonly used 
screening tool to determine body fatness. BMI was measured through the use of the Smart 
WeighTM Digital BMI Body Fat Weight Scale.  BMI is typically calculated as weight 
(kilograms)/height2 (square meter). Typical classifications for body fatness are as follows:  
 30 
below 18.5—underweight, 18.5-24.9—normal weight, 25.0-29.9—overweight, and 30.0 and 
above—obese (CDC, 2015b).  
Interventions 
Health Effects of Smoking (Copeland, 2015). Health Effects of Smoking is a 
systematic B-MI for smoking cessation. It incorporates both the principles of MI and 
personalized, health-based feedback for smoking cessation. This B-MI consists of standard MI-
based strategies and techniques including, establishing rapport, assessing motivation, readiness, 
and confidence to quit (through the use of scaling questions), decisional balancing tasks and 
identifying and generating a plan of action. The systematic intervention includes personalized 
health feedback comments, in which the therapist discusses the biological feedback (i.e., an 
individual’s cardiovascular functioning/blood pressure, carbon monoxide readings, pulmonary 
lung functioning/lung age). Additionally, the protocol provides the patient with worksheets, to 
allow her to review her biological feedback information, as well as work alongside the 
therapist completing the decisional balance tasks and generating a plan for action. Preliminary 
data suggests that the individuals receiving the Health Effects of Smoking B-MI protocol 
progressed in terms of stages of change algorithm (i.e., moved from precontemplation to 
contemplation) 3-months following the intervention (Copeland, 2015). The Health Effects of 
Smoking B-MI protocol served as the active treatment condition in the present study. 
All therapists administrating the B-MI protocol were trained regarding the general 
protocol and the main components of MI. This training included reading Motivational 
Interviewing 3rdedition (Miller & Rollnick, 2013) and watching training videos (Hettema, 
2009). Furthermore, all therapists were supervised in weekly practicum meetings to discuss 
treatment and therapeutic techniques to insure that therapists were adhering to the protocol.  
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Yosemite: The High Sierras (Meyer, 2012). This documentary explores the 
geographical area and features included within the Sierra Mountain range. This documentary 
acted as the control condition in the present study to control for time of B-MI intervention. 
Procedure 
Louisiana State University’s Institutional Review Board approved all study procedures, 
including recruitment advertisements and practices. Participants were recruited via 
advertisements at various locations around the community (e.g., libraries, churches, etc.) and 
on campus. Additionally, paid advertisements were placed weekly on Internet platforms (e.g., 
Craigslist). If interested in participating in the study, the advertisement instructed the 
participants to call or E-mail the experimenter. Participants were then contacted by the 
experimenter to complete a phone screening to determine study eligibility. If the participant 
smoked at least ten cigarettes per day and did not meet any additional exclusion criteria, she 
was invited to participate in the study.  
Participants self-selected an experiment date from given available times and arrived for 
the study portion in the Psychological Services Clinic (PSC) in Johnston Hall on the LSU 
campus. When participants arrived for the scheduled study session, they were asked to 
complete the informed consent form for the experimental session. They were then asked to 
provide a carbon monoxide reading to verify eligibility status and a urine sample for FSH 
analysis, utilizing the Vitalograph-BreathCO Monitor and Rapid Response Menopause 25mIU 
FSH (Urine) Test Cassette. Any participant that had a carbon monoxide level below 10 parts 
per million (ppm) or an FSH level below 25 mIU/mL was not eligible to participate in the 
study visit.  
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Following the carbon monoxide reading and urine sample collection, participants had 
their height and weight taken to determine body mass index, as well as have blood pressure, 
heart rate and lung age recorded, utilizing the Vitalograph- Lung Age Indicator and Walgreens 
Digital Blood Pressure Monitor HD2000, respectively. Additionally, they completed the 
URICA, SEQ-12, MRS, MTSS, SWEET, and PANAS.  
Participants, based upon random group assignment, then either engaged in the B-MI or 
control group. This process utilized urn randomization controlling for age, nicotine dependence 
(as measured by the FTND; Heatherton et al., 1991), body mass index, and the number of pack 
years. Number of pack years was calculated by multiplying the number of cigarettes currently 
smoked per day by the number of years the participant has smoked and dividing this number 
by 20). A pack year is a unit of measurement for the quantification of the history of cigarette 
consumption (Prignot, 1987). Participants in the B-MI intervention participated in a one-
session, 1-hour B-MI intervention regarding smoking cessation (Copeland, 2015). This 
intervention was led by the study therapist and followed the B-MI protocol. To control for 
time, those who did not participate in the B-MI viewed a 1-hour video on the	Yosemite 
National Park (Meyer, 2012; similar procedure for controlling time utilized in Waldo, 2014). 
Following the B-MI or 1-hour video, all participants then completed URICA, MTSS, 
and SEQ-12. Once these measures were completed; the participant received $50 for completion 
of the study. FSH levels fluctuate, and a confirmatory FSH test of above 25 mlU/ml is needed 
to confirm postmenopausal status. Accordingly, the participants were then given a FSH urinary 
kit, including explicit instructions to take home, and a follow-up phone call at seven days’ 
post-intervention was scheduled at the participant’s convenience. A telephone visit was 
selected to decrease the burden of transportation to laboratory and thus improve study 
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retention. Seven days following the study session, the study therapist called the participant to 
obtain the results of the FSH urine analysis and complete the URICA, MTSS and SEQ-12 over 
the phone. If the study therapist was unable to reach the participant (e.g., call went to 
voicemail), three additional efforts were made to contact the participant. Participants were then 
thanked for their participation and referred to the LSU Smoking Cessation Group at the PSC if 
a desire to quit was expressed at any point during the study visit.    
Data Analytic Strategy 
 Differences in demographic data between the treatment and control groups regarding 
age, race and ethnicity, education level, body mass index, daily smoking rate, number of years 
smoked, level of nicotine dependence (as measured by the FTND), number of pack-years, 
number of previous quit attempts, alcohol use (as measured by the AUDIT) and HT status (i.e., 
currently taking an HT) were calculated. These differences were calculated utilizing one-way 
analyses of variance (ANOVAs) for each of the seven continuous variables. Chi-square 
analyses were conducted on the three categorical variables (i.e., race/ethnicity, education level 
and HT status).  
 Hypothesis 1. In order to determine the impact of variables, including negative affect, 
weight concerns and menopausal symptom severity on motivation and readiness to quit 
smoking, correlations were calculated between the negative affect scale of the PANAS, 
SWEET and MRS, as well as baseline measures of URICA and MTSS. Further, two multiple 
linear regressions were conducted to assess whether the combination of negative affect, weight 
concerns, and menopausal symptom severity predicted motivation and readiness to quit 
smoking at baseline. Independent variables included the negative affect scale of the PANAS, 
SWEET, and MRS, while the first linear regression included the dependent variable of the 
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baseline measure of URICA. The second linear regression included the same independent 
variables (PANAS, SWEET, and MRS) and the dependent variable included the baseline 
measure of MTSS. For both regressions, a standard enter method was applied and all 
independent variables were entered simultaneously into the models. Additionally, for each 
regression, R2 was calculated to assess the amount of variance the set of independent variables 
accounted for and the significance of the betas will be examined to see which of the 
independent variables were contributing uniquely. 
Hypotheses 2-5. To determine the effects of the B-MI on motivation, readiness and 
self-efficacy to quit smoking across time, a repeated measures multivariate analysis of variance 
(MANOVA) were conducted. Intervention group (control vs. B-MI) and Time (baseline [T1], 
following intervention [T2] and 1-week follow-up [T3]) were entered as the independent 
variables. The SEQ-12 (measures self-efficacy to quit smoking), URICA (measures readiness 
to quit smoking), and MTSS (measures motivation to quit smoking) were entered as the 
dependent variables.  
RESULTS 
A total of 198 individuals contacted the laboratory to participate in the present study. 
Of these individuals, 43 individuals were eligible to participate, and 22 participants completed 
the initial study session. Two participants were lost to follow-up and thus excluded from 
subsequent analyses, due to no having biological confirmation of postmenopausal status. An 
additional two participants were deemed ineligible at follow-up due to having FSH levels 
below 25 mlU/ml. Eighteen participants completed the initial study session and follow-up 
questionnaires. See Figure 1 for additional recruitment details.  
 35 
Of those participants completing the initial study session and follow-up procedures (n= 
18), the average age was 54.78 (SD=6.47) and participants were primarily non-Hispanic 
(94.44%), Caucasian (77.80%) females. The majority of the participants were overweight, with 
an average BMI of 26.72 (SD=8.23), and moderately nicotine dependent (FTND; M=5.17, 
SD=1.69). Ten participants were randomized to the control treatment group, and eight 
participants were randomized to the B-MI treatment group. See Table 1 for complete 
demographic data. No differences were observed between the group groups in regards to age, 
race and ethnicity, education level, body mass index, daily smoking rate, number of years 
smoked, level of nicotine dependence (as measured by the FTND), number of pack-years, 
number of previous quit attempts, alcohol use (as measured by the AUDIT) and HT status (i.e., 
currently taking an HT).  
Specific Aim 1 
 Hypothesis 1. In order to determine the impact of negative affect, weight concerns, and 
menopausal symptoms on motivation and readiness to quit smoking among postmenopausal 
females, correlations were calculated between the negative affect scale of the PANAS, SWEET 
and MRS, as well as baseline measures of URICA and MTSS. See Table 2 for descriptive data 
related to the above-mentioned variables.  
 Contrary to expectations, negative affect was not correlated with URICA, r(16)=0.13, 
p= 0.61 and MTSS, r(16)=0.23, p=0.37. In regards to smoking-related weight concerns, 
SWEET total score was positively correlated with baseline readiness to quit (measured via the 
URICA), r(16)=0.50, p=0.04, with higher SWEET total scores associated with higher ratings 
of readiness to quit smoking, but motivation to quit smoking (measured via MTSS) was not 
significantly correlated with the SWEET total score, r(16)=0.08, p=0.76. Menopausal 
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symptoms severity was positively correlated with motivation to quit smoking, r(16)=0.50, 
p=0.04, with more severe menopausal symptom severity indicative of increased reports of 
motivation to quit smoking, but not readiness to quit, r(16)=0.37, p=0.14. 
n= 198  
contacted laboratory recruitment line 
n= 70 




not interested in 
study at screening 
n= 43 





completed study session 
(n=12 B-MI; n=10 control) 
  
n= 21 
no showed to study session and 




(n=10 B-MI; n=10 control) 
 
n= 2 
lost to follow-up 
(n=2 B-MI) 
n= 2 
excluded based upon menopause 
confirmation (n=2 B-MI)	 
n= 18 
completed all study procedures 
(n=8 B-MI; n=10 control) 
Figure 1. Participant recruitment data.  
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Table 1. Differences between treatment groups (B-MI vs. Control) demographic variables (n = 18) 
 Treatment Group 
 
     
Demographic Variable B-MI Group Control 
Group 
 B-MI Group  
95% CI 
Control Group 
 95% CI 
F or 
χ2 
p Cohen’s D  
or  
Cramer’s V 
Mean Age (SD) 55.13 (7.72) 54.50 (5.70) [48.67, 61.58] [50.42, 58.58] 0.04 0.85 0.09 
Cigarettes per day 15.75 (4.62) 17.30 (4.79) [11.89, 19.61] [13.88, 20.72] 0.48 0.50 0.33 
Years smoked 39.63 (7.52) 29.80 (17.35) [33.34, 45.91] [17.39, 42.21] 2.21 0.16 0.74 
Pack years 31.06 (10.54) 26.71 (16.28) [22.25, 39.88] [15.06, 38.35] 0.43 0.52 0.32 
Number of quit 
attempts 
5.38 (4.84) 4.50 (4.09) [1.33, 9.42] [1.57, 7.43] 0.17 0.68 0.20 
CO level 26.00 (19.11) 19.50 (5.62) [10.03, 41.98] [15.47, 23.52] 1.06 0.32 0.46 
FTND 5.13 (1.73) 5.20 (1.75) [3.68, 6.57] [3.95, 6.45] 0.01 0.93 0.04 
Lung Age 80.75 (8.94) 84.90 (25.53) [82.28, 97.22] [66.64, 103.16] 0.26 0.62 0.23 
BMI 25.85 (7.56) 27.42 (9.07) [19.53, 32.17] [20.93, 33.91] 0.15 0.70 0.19 
Body fat (%) 32.16 (11.27) 39.08 (24.19) [22.74, 25.63] [21.78, 56.38] 0.55 0.47 0.37 
GDS 5.25 (3.45) 4.30 (3.97) [1.22, 2.36] [1.26, 1.46] 0.28 0.60 0.26 
AUDIT 4.64 (6.95) 2.90 (3.60) [-1.18, 10.43] [0.32, 5.48] 0.47 0.51 0.31 
Days until follow-up 8.00 (1.2) 7.7 (1.25) [7.00, 89.00] [6.81, 8.60] 0.27 0.61 0.25 
Race (%)     2.09 0.55 0.34 
     Caucasian  75.00% 80.00% --- ---    
     African American 12.50% 10.00% --- ---    
     Multiracial 12.50%     0% --- ---    
     Other     0% 10.00% --- ---    
Ethnicity (%)     1.32 0.25 0.27 
     Hispanic 12.50% 0.00% --- ---    
     Non-Hispanic 87.50% 100.00% --- ---    
Education level (%)     2.96 0.23 0.41 
     High school/GED 37.50% 40.00% --- ---    
     Some college 37.50% 50.00% --- ---    
     Bachelor’s degree 25.00% 0.00% --- ---    
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(Table 1 continued) 
 
Current HT status (%) 









     Taking HT 12.50% 0.00% --- ---    
     Not taking HT    87.50% 100.00% --- ---    
Surgical menopause   	 	 0.68 0.41 0.19 
     Yes 37.50% 80.00% ---	 ---	    
     No 62.50% 20.00% ---	 ---	    
 	 	 	 	    
Note. B-MI Group= Brief Motivation Interviewing Group; SD= Standard Deviation; CI = Confidence Interval; FTND= Fagerström Test for 




Table 2. Differences between treatment and control groups for negative affect, smoking-related weight concerns, menopausal 
symptoms severity and baseline measures of motivation and readiness to quit (n = 18) 
	
 Treatment Group 
 
     
Variable B-MI Group Control 
Group 
 B-MI Group  
95% CI 
Control Group 
 95% CI 
F p Cohen’s 
   D 
MTSS at baseline (SD) 3.63 (1.60) 2.70 (1.60) [2.29, 4.96] [1.58, 3.82] 1.52 0.27 0.58 
URICA at baseline 7.94 (0.81) 8.19 (1.63) [7.27, 8.62] [7.02, 9.35] 0.14 0.71 0.19 
PANAS 































     somatic 6.50 (3.34) 4.80 (2.90) [3.71, 9.29] [2.73, 6.87] 1.34 0.26 0.54 
     urogenital 3.50 (2.27) 2.30 (2.06) [1.60, 5.40] [0.83, 3.77] 1.38 0.26 0.55 
     psychological 5.75 (2.71) 4.50 (2.68) [0.96, 3.48] [0.85, 2.59] 0.96 0.34 0.46 
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(Table 2 continued)        
        
 Treatment Group 
 
     
Variable B-MI Group Control 
Group 
 B-MI Group  
95% CI 
Control Group 
 95% CI 
F p Cohen’s 
   D 
        
SWEET 















     suppress appetite 6.25 (2.49) 7.00 (2.75) [4.17, 8.33] [5.03, 8.97] 0.36 0.56 0.29 
     prevent overeating 4.63 (0.92) 5.60 (2.68) [3.86, 5.39] [3.69, 7.51] 0.96 0.34 0.48 
     body dissatisfaction 2.38 (0.74) 2.70 (1.34) [1.75, 3.00] [1.74, 3.67] 0.38 0.55 0.30 
     withdrawal 3.38 (1.69) 4.40 (2.07) [1.97, 4.78] [2.92, 5.88] 1.28 0.27 0.54 
Note. B-MI Group= Brief Motivation Interviewing Group; SD= Standard Deviation; CI = Confidence Interval; MTSS= Motivation To 
Stop Smoking; URICA= University of Rhode Island Change Assessment; PANAS= Positive and Negative Affect Scale; MRS= 
Menopause Rating Scale; SWEET= Smoking-Related  
 
 Given that the MRS and SWEET have subscales, exploratory analyses were conducted to investigate the relationship between 
specific subscales and motivation and readiness to quit. The MRS subscale of somatic menopausal symptoms was positively correlated 
with motivation to quit, r(16)=0.50, p=0.03; however it was not correlated with readiness to quit, r(16)=0.37, p=0.14. The urogenital 
and psychological subscales were not significantly correlated with motivation or readiness to quit smoking. Additionally, the SWEET 
subscale of smoking to prevent overeating was positively correlated with readiness to quit, r(16)=0.66, p<0.01; the other three SWEET 
subscales, smoking to suppress appetite, smoking to cope with body dissatisfaction, and withdrawal-related appetite increases, were not 
significantly correlated with motivation or readiness to quit smoking. See Table 3 for complete correlation data.
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Table 3. Pearson’s correlations for negative affect, smoking-related weight concerns, 
menopausal symptoms severity and baseline measures of motivation and readiness to quit 
(n = 18; df= 16) 
Note. PANAS= Positive and Negative Affect Scale; MRS= Menopause Rating Scale; 
SWEET= Smoking-Related Weight Eating Episodes Test; *p ≤ 0.05; ** p ≤ 0.01 
 
Table 4. Multiple linear regressions of potential predictors of motivation and readiness to 
quit smoking 
 ΔR2 ΔF β t p 





2.99   
 
0.07 
   PANAS- negative affect scale   0.29 1.37 0.19 
   MRS- total score   0.29 1.34 0.20 
   SWEET- total score   0.44 2.04 0.06 
      
 






















PANAS-negative affect scale 0.13 0.23  
MRS- total  0.50* 0.37  
MRS- somatic scale  0.50* 0.16  
MRS- urogenital scale 0.16 0.22  
MRS- psychological scale 0.31 0.38  
SWEET- total 0.08  0.50*  
SWEET- suppress appetite scale 0.14 0.33  










SWEET- prevent overeating scale 0.13    0.66**  
SWEET- body dissatisfaction scale -0.17 0.34  
SWEET- withdrawal scale 0.21 0.31  
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(Table 4 cont.)      
   MRS- total score   0.54 2.30 0.04 
   SWEET- total score   -0.05 -0.22 0.83 
Note. PANAS= Positive and Negative Affect Scale; MRS= Menopause Rating Scale; 
SWEET= Smoking-Related Weight Eating Episodes Test 
 
 To test the hypothesis that the combination of negative affect, weight concerns, and 
menopausal symptom severity predict readiness to quit smoking at baseline a multiple linear 
regression was conducted. A non-significant regression equation was found, R2=0.39, 
F(3,14)=2.99, p=0.07, f2=0.64. Although not statistically significant, 39% of the variance in 
readiness to quit can be attributed to negative affect, weight concerns and menopausal 
symptom severity. Additionally, to test whether these variables predict motivation to quit 
smoking at baseline, a second multiple linear regression was conducted. A non-significant 
regression equation was found, R2=0.29, F(3,14)=1.92, p=0.18, f2=0.41. Results are included 
in Table 4. 
Specific Aim 2 
 Hypotheses 2-3. To investigate the hypothesis that B-MI would increase motivation 
and readiness to quit smoking across time, a mixed-model MANOVA was conducted. Results 
indicated no significant main effect of Treatment Group, F(2,15)=0.63, p=0.55, partial η2 = 
0.08; however, there was a significant main effect of Time, F(4,13)=3.20, p=0.05, partial η2 = 
0.50. The interaction between Time and Treatment Group was not significant, F(4,13)=0.68, 
p=0.62, partial η2 = 0.17. The significant results, were followed-up with a repeated measures, 
within subjects MANOVA; this provided significant results across time points, F(2,32)=4.68, 
p=0.02, partial η2 = 0.23. Follow-up ANOVAs investigated the results across time points, and 
both MTSS, F(2, 16)=3.08, p=0.06, d=0.88 and URICA, F(2,16)=2.84, p=0.07, d=0.85,  
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approached significance. Figure 2 illustrates means across time points and Table 5 displays 
these means. Pairwise comparisons comparing each time point were not significant (Table 6).  
Table 5. Means and standard deviations of motivation and readiness to quit smoking  
 Time   
Measure    Baseline    Post-treatment Follow-up  
MTSS (SD)    
     All participants (n=18) 3.11 (1.61) 2.94 (1.70) 3.50 (1.58) 
     B-MI group (n=8) 3.63 (1.60) 3.38 (1.85) 3.63 (1.60) 
     Control group (n=10) 2.70 (1.57) 2.60 (1.58) 3.40 (1.65) 
   URICA (SD)    
     All participants (n=18) 8.08 (1.30) 8.44 (1.60) 8.63 (1.97) 
     B-MI group (n=8) 7.95 (0.81) 8.45 (1.55) 8.88 (1.86) 
     Control group (n=10) 8.19 (1.63) 8.44 (1.72) 8.43 (2.14) 
Note. MTSS= Motivation to Stop Smoking; URICA= University of Rhode Island Change 
 
 
Table 6. Pairwise comparisons of URICA and MTSS at each time point 




p 95% CI Cohen’s 
D 
MTSS 1 2 0.18 0.15 0.78 [-0.23, 0.58] 0.10 
  3 -0.35 0.25 0.55 [-1.02, 0.32] 0.24 
 2 1 -0.18 0.15 0.78 [-0.58, 0.23] --- 
  3 -0.53 0.23 0.11 [-1.14, 0.09] 0.34 
 3 1 0.35 0.25 0.55 [-0.32, 1.02] --- 
  2 0.53 0.23 0.11 [-0.91, 1.14] --- 
URICA 1 2 -0.38 0.20 0.21 [-0.90, 0.15] 0.25 
  3 -0.59 0.31 0.23 [-1.42, 0.25] 0.34 
 2 1 0.38 0.20 0.21 [-0.15, 0.90] --- 
  3 -0.21 0.23 1.00 [-0.81, 0.40] 0.11 
 3 1 0.59 0.31 0.23 [-0.25, 1.41] --- 
  2 0.21 0.23 1.00 [-0.40, 0.81] --- 
Note. MTSS= Motivation to Stop Smoking; URICA= University of Rhode Island Change 
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Specific Aim 3 
 Hypotheses 4-5. To investigate the hypothesis that MI would increase self-efficacy 
(internal and external) to quit smoking across time, a second mixed-model MANOVA was 
conducted. Results indicated no significant main effect for Treatment Group, F(2,15)=0.82, 
p=0.46, partial η2 = 0.10, Time, F(4,13)=1.21, p=0.36, partial η2 = 0.27, or the interaction 
between Time and Treatment Group, F(4,13)=1.69, p=0.21, partial η2 = 0.34. Figure 3 
illustrates means across time points. Given the lack of significant main effect results, follow-up 







Figure 2. Means of motivation and readiness to quit smoking  
 





























 A mixed model MANOVA investigating whether MI would increase motivation and 
readiness to quit smoking across time was also conducted including the AUDIT score as a 
covariate, given the strong relationship between alcohol and tobacco consumption in the 
literature. However, similar to the above-described analyses there were no significant main 
effect for Treatment Groups, F(2,14)=1.01, p=0.20, partial η2 = 0.13, but there was a 
significant main effect of Time, F(4,12)=5.52, p=0.01, partial η2 = 0.67. Both the interaction 
between Time and Treatment Group, F(4,12)=0.67, p=0.63, partial η2 = 0.18, and Time and 
AUDIT score, F(4,12)=1.99, p=0.16, partial η2 = 0.40, were not significant. These findings 
indicate that problematic drinking did not affect above-mentioned findings.  
 Given the results that indicated that motivation and readiness to stop smoking increased 
at follow-up, exploratory analyses were conducted to see if these findings impacted the number 
of cigarettes smoked per day as measured at baseline and follow-up. Results showed a 
significant decrease (M= 3.87, SD=4.25) in cigarettes smoked per day from baseline to follow-
up, t(17)=3.86, p<0.01, d=0.74, with a large effect size. Additionally, a correlation was also 
run using the GDS as a measure of negative affect to further explore the impact of negative 
affect, on motivation and readiness to quit smoking. Similar to the negative affect scale of the 
PANAS, the GDS did not significantly correlated to motivation to stop smoking (MTSS), 
r(16)=-0.74, p=0.77, or readiness to quit (URICA), r(16)=-0.14, p=0.58.  
DISSCUSSION 
The present study sought to explore the barriers related to postmenopausal female 
smokers’ motivation and readiness to make a quit attempt, as well as enhance this motivation 
and readiness to make a behavioral change. Given that postmenopausal females continue to 
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smoke despite significantly increased health-related concerns related to low levels of estrogen 
in combination with the antiestrogenic effects of nicotine consumption, it is especially 
important to identify significant barriers to quit smoking and to motivate this population to 
engage in smoking cessation treatment. The present study identified that increased menopausal 
symptoms severity and smoking-related weight concerns were related to increased motivation 
to quit smoking. Additionally, although a B-MI did not significantly increase motivation or 
readiness to quit smoking when compared to the control condition, participants in both groups 
did increase on measures of motivation and readiness to quit from pre-treatment to follow-up.  
Previous research has established that postmenopausal females endorse high levels of 
smoking-related weight concerns; however, despite these concerns, these females are more 
likely to enter smoking cessation than premenopausal counterparts (Copeland et al., 2006). The 
current results expand this research to demonstrate that higher levels of smoking-related weight 
concerns, especially concerns related to smoking to prevent overeating, are associated with 
higher levels of endorsed readiness to quit smoking. Additionally, results approached 
significance, which showed that smoking-related weight concerns accounted for 44% of the 
variance related to readiness to stop smoking at baseline. This may be related to augmented 
health concerns surrounding weight and smoking behaviors (Copeland et al., 2006; Ockene, 
1987). Future research may explore the effectiveness of incorporating a weight loss 
intervention into smoking cessation treatment among postmenopausal smokers, to 
simultaneously address concerns related to both weight and smoking.  
Reports of menopausal symptoms and smoking cessation have indicated that the 
presence of menopausal symptoms is associated with decreased rates of abstinence (Copeland 
et al., 2016). However, current results indicated a discrepant effect, with increased reports of 
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menopausal symptoms associated with increased endorsed motivation to make a cessation 
attempt. This contrary finding provides evidence that postmenopausal females may have 
significant concerns surrounding health and thus augment motivation for cessation to 
potentially combat these concerns. Previous research has suggested that many older smokers 
are motivated to quit due to smoking-related illnesses (Ockene, 1987). Furthermore, research 
identified that older women (aged 61-92 years old) express that health risks often drive the 
need to lose weight, indicating that health evaluation and health orientation are more important 
to body satisfaction (Hurd Clarke, 2002; Copeland et al., 2006; Jafary, Farahbakhsh, 
Shafiabadi, & Delavar, 2011). This finding may be extrapolated to smoking cessation, as older 
women also indicate that health evaluation is correlated with quality of life (Jafary et al., 
2011). This is supported in the present study, as both total score and somatic menopausal 
symptoms (e.g., complaints associated with increased sweating/flushing, cardiac discomfort, 
sleep problems, joint/muscle pain) were associated with increased motivation for cessation. 
Contrary to the hypotheses, negative affect (measured via PANAS-negative affect 
scale) was not correlated nor did it predict motivation or readiness to quit smoking at baseline. 
The negative affect scale of the PANAS produces scores ranging from 10 to 50, with higher 
scores being indicative of higher levels of negative affect (Watson et al., 1988). Furthermore, 
depressive symptoms (measured via GDS) did not correlate with motivation or readiness to 
quit smoking and participants across groups scored in the “mild” depressive symptom range. 
Research indicates that greater negative affect is often associated with a greater desire to 
smoke to relieve the negative affect (Johnson & McLeish, 2016). The low baseline levels of 
negative affect and depressive symptoms endorsed in the current sample likely affected the 
present results. The relatively low scores on these measures potentially represent a decreased 
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need to smoke to relieve negative emotions and thus explains why one’s negative emotions 
would not impact intentions surrounding quitting smoking as previously expected. 
The present study did not demonstrate B-MI as an effective strategy to increase 
motivation or readiness to make a cessation attempt. Although this did not support the 
hypotheses, the sample size in the present study was smaller than the proposed sample required 
to detect the treatment response, which may explain a lack of differences between treatment 
groups. However, despite the low sample size, the present study did detect an increase in 
motivation and readiness to quit smoking across time, with a large effect size (Cohen, 1988).  
Furthermore, results indicated that across groups, participants decreased smoking rate by 
approximately 20-30% per day during the 7-day follow-up, reporting a mean decrease in 
cigarettes per day at follow-up (M= 3.87, SD=4.25). These results indicate that it is beneficial 
to encourage postmenopausal females to evaluate smoking behaviors, as well as physical and 
psychological symptoms, as both groups did during the baseline assessments. This not only 
increased motivation and readiness to make a smoking cessation attempt but also helped 
postmenopausal females cut down their daily smoking rate, regardless of treatment group.   
There is also evidence from meta-analyses, showing that individuals that are younger in 
age and endorse lower levels of nicotine dependence and motivation to quit smoking may 
exhibit an increase in response to MI (Hettema & Hendricks, 2010). Given that the participants 
in the present study were older females, who identified as moderately nicotine dependent 
(FTND score, M=5.17, SD=1.69) and on average endorsed intention to quit smoking (MTSS 
score at baseline, M=3.11, SD=1.61, 3= “I want to stop smoking but haven't thought about 
when”), this may have decreased the response to the B-MI intervention. Thus, it may be more 
advantageous to tailor a B-MI intervention, which incorporates the health concerns related to 
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weight and vasomotor symptoms of menopause in addition to tobacco-related concerns as 
observed in the present study. Further, a meta-analysis of MI effectiveness within the context 
of brief follow-up shows that MI produces a significant treatment effect when compared to a 
minimally active treatment as opposed to control treatments (Hettema & Hendricks, 2010). It 
may be beneficial for future research to test a B-MI intervention tailored to postmenopausal 
females against another active treatment.  
The B-MI also did not increase internal or external self-efficacy to change. Self-
efficacy to change is described by Miller and Rollnick (2013) as a critical component to 
fostering positive behavioral change. In light of this, it is not surprising the present intervention 
did not increase internal or external self-efficacy, as the B-MI had no observable effect on 
motivation for behavioral change. In order to foster self-efficacy, it is necessary for hope and 
likelihood of behavioral change to be supported (Center for Substance Abuse Treatment 
[CSAT], 1999).  The present study was not a treatment study and did not explicitly recruit 
individuals who wanted to quit smoking. Thus, it is possible that participants did not feel as 
though the prospect of a successful cessation attempt was supported within the intervention and 
impacted the fostering of their self-efficacy to make a behavioral change. Further, it has been 
suggested that education increases self-efficacy among those making positive behavioral 
changes in the context of substance use (CSAT, 1999; Miller & Rollnick, 2013). The present 
intervention did not explicitly provide education related to specific concerns related to 
postmenopausal female smokers, including menopausal symptoms and weight-related 
education. Incorporating specific education into future MI interventions targeting this 
population, including how smoking impacts postmenopausal weight gain and the somatic 
symptoms of menopause, may support increased self-efficacy for smoking cessation.  
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Limitations 
 The present study has several limitations that warrant mention. First, the sample size in 
the present study was smaller than the proposed sample determined a priori to detect a 
treatment response, and it included a limited and potentially biased participant pool. 
Participants included postmenopausal females who were able to contact the laboratory 
recruitment line via telephone or E-mail, representing a sampling bias. These individuals were 
able to attend study sessions on weekdays and evenings and provide their own transportation to 
these study sessions. While no treatment response was detected, a main effect of time on 
motivation and readiness to quit, as well as on cigarettes smoked per day, was found despite 
the limited sample size. Furthermore, both findings exhibited meaningful effect sizes, 
indicating clinically significant observations. While findings suggest positive outcomes for 
engaging postmenopausal females in contemplating smoking cessation treatment, these results 
should be viewed with caution given the small sample size and its limited generalizability.  In 
light of this small sample size, future studies should consider planning data analysis for small 
sample sizes, given the present demonstrated recruitment difficulties.  
 The correlational design of the exploration of barriers to motivation to impact smoking 
prevents casual inferences to be drawn about the relationship between negative affect, weight 
concerns, menopausal symptoms and motivation and readiness to quit smoking. Future 
research may conduct experimental designs that investigate the impact of these barriers on 
motivation and readiness to make a cessation attempt. Additionally, the study was conducted in 
the Southeast United States, a geographical area that has higher smoking rates when compared 
to other parts of the country (e.g., Northeast, West; USDHHS, 2014). Thus generalizability of 
results may be limited to certain regions of the country.  
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 The current study did not utilize standardized assessment tools, including ratings of 
global adherence to MI protocol and behavior tallies to measure elements of MI adherence (see 
Moyers, Manuel, & Ernst, 2015 for example). Given that the study therapists were actively 
enrolled in weekly clinical supervision to discuss implementing the intervention, the present 
study did not formally assess for adherence to the study protocol, as sessions were informally 
assessed during supervisions meetings. Future studies of B-MI within the population would 
benefit from including measures of protocol adherence. Finally, the study only included a one-
week follow-up. In light of evidence that MI’s effect may wane over time, a longer follow-up 
would have explored whether or not findings would decrease over a longer time period.  
 Despite these limitations, the present study exhibited several strengths. To the author’s 
knowledge, it is the first study of its kind to investigate the barriers to motivation and readiness 
to make a cessation attempt among postmenopausal female smokers and the impact of B-MI on 
motivation and readiness to make a behavioral change among this population. It also 
biologically confirmed FSH level at two-time points to ensure participants were 
postmenopausal with stable hormone levels and not in pre- or perimenopause. Lastly, the 
present study maintained the majority of its participants through the study procedures, only 
losing two individuals (9% of participants) to follow-up. 
Implications and future directions  
 The present study identified smoking-related weight concerns, specifically surrounding 
smoking to prevent overeating, as related to increased motivation to quit smoking. The study 
identified menopausal symptom severity, most notably somatic symptoms, was associated with 
increased readiness for cessation. Additionally, results indicate that motivation and readiness to 
quit increased over time and cigarettes per day decreased from baseline to follow-up. Future 
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research should investigate how these barriers affect a smoking cessation attempt. Furthermore, 
given that the present study’s detected an increase in motivation and readiness to quit across 
treatment groups, future studies may consider powering the study to include analysis 
percentage of point prevalence rates of abstinence or reduction in cigarettes per day between 
the subscales of the URICA (Precontemplation, Contemplation, Action, and Maintenance; 
DiClemente, et al., 1991). This would allow future research to investigate the movement 
between the stages of change and provide more insight to improve cessation outcomes among 
postmenopausal females.   
Given that previous research has demonstrated that females will enter smoking 
cessation treatment despite health concerns, including weight concerns, it would be beneficial 
to explore how these noted barriers impact cessation treatment (Copeland et al., 2006; McVay 
& Copeland, 2011). For instance, research has shown that pre-treatment measures of variables 
including weight concerns significantly increased treatment drop out rates (Copeland et al., 
2006). Research also suggests that nicotine replacement therapy (NRT) may provide short-term 
assistance for postmenopausal females making a quit attempt; however, NRT has not 
demonstrated to be helpful among postmenopausal smokers with a history of depression or 
with post-cessation weight gain (Oncken, Cooney, Feinn, Lando, & Kranzler, 2007; Allen, 
Kleppinger, Lando, & Oncken, 2013). Exploring these barriers’ effect on a quit attempt may 
provide health care providers with valuable information to assist postmenopausal females in 
entering smoking cessation treatment, as well as potentially tailoring treatment to individuals. 
Furthermore, it would be advantageous to investigate whether a MI-based intervention 
that was tailored to include education on such barriers (e.g., smoking-related weight concerns 
and menopausal symptoms) would positively affect a quit attempt. Previous research has 
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indicated that smoking cessation programs designed to address weight maintenance, depressive 
symptoms and peer support needs (e.g., group vs. individual treatment) may be beneficial when 
making a cessation attempt (Copeland et al., 2006). Thus, it could be helpful to include specific 
treatment components to target smoking-related weight concerns and menopausal symptoms 
and thus increase motivation to engage in cessation treatment.  
 Given the implications that postmenopausal females’ motivation may be affected by 
health concerns surrounding weight and physical symptoms, it would be interesting to explore 
the relationship between health literacy, motivation/readiness to engage in a quit attempt and 
self-efficacy to quit (Copeland et al., 2006; Hurd Clarke, 2002; Jafary et al., 2011; Ockene, 
1987). Lower health literacy has been associated with not only less knowledge regarding 
smoking-related health risks and increased dependence. Previous research has demonstrated 
that lower health literacy also more positive consequences of smoking and less negative 
expectancies of smoking; overall, lower health literacy was associated with less knowledge of 
the health risks of smoking (Stewart et al., 2013). Thus, identifying and potentially targeting 
low health literacy among this population with education regarding post-cessation weight and 
impact of cessation on menopausal symptom severity may increase motivation to engage in 
smoking cessation.   
Summary  
 In summary, the present study is the first to explore barriers related to motivation and 
readiness to make a quit attempt as well as employ a B-MI intervention to enhance motivation 
and readiness for cessation in postmenopausal females. Smoking-related weight concerns, 
specifically surrounding smoking to prevent overeating, were identified as related to increased 
motivation to quit smoking and menopausal symptoms severity, including somatic symptoms, 
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were associated with increased readiness for cessation. Additionally, although B-MI did not 
increase motivation or readiness to quit, results indicate that across groups, motivation and 
readiness to quit increased over time and cigarettes per day decreased from baseline to follow-
up. These results provide important insight into enhancing engagement in a smoking cessation 
treatment among this population, who experiences increased health-related concerns related to 
low levels of estrogen in combination with the antiestrogenic effects of nicotine use. Future 
research based upon these results could explore the impact of these barriers on a cessation 
attempt, as well as to tailor treatments to include concerns unique to this population of 
smokers, including smoking-related weight concerns,	menopausal symptoms severity and 
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Okay to leave a message?   YES NO 
 
1. Gender:  Female Male 
2. Age:____________________ 
3. Number of Cigarettes per day: ____________________ 
4. Number of years smoking (continuously): ____________________ 
5. How many months since last menses (period)?: ____________________ 




Please respond to each of the following questions. 
 
1. Gender:  Female  Male 
2. Age:    __________________________________ 
3. Race:    White  Black  American Indian Asian  
  Multirace Other 
4. Ethnicity:  Hispanic Non-hispanic 
5. Relationship Status:  
Single    In a relationship    Married Divorced Widowed
 Other 
6. Highest Level of Education Completed:   
Less than 8th grade   8th Grade     Some High School 
High school graduate/GED Some College   Bachelor’s degree  
Some Graduate School  Graduate Degree  
7. In the past year have you had a period?   Yes  No 
a. Date of last period:________________________________________ 
8. Do you currently take any daily medications?:   Yes  No 
a. If Yes, what type: _____________________________________________ 
9. Do you smoke cigarettes daily?:    Yes  No 
a. If yes, how many cigarettes do you smoke per day?: _________________ 
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10. How many years have you been smoking?: _________________    
11. What is your preferred brand of cigarettes?:  _____________________________ 
12. Have you ever tried to quit smoking before?:   Yes  No 
a. If Yes, how many times have you tried?  _______________________ 
13. Have you ever undergone menopause as the result of a surgery?:   Yes No 
a. If Yes, what procedure?  ____________________________________ 
14. Are you currently taking a hormonal replacement therapy? YES NO 
a. If Yes, what type?  ___________________________________________ 
 
Fagerström Test for Nicotine Dependence (FTND) 
 
Please read each question below. For each question check the answer choice which best 
describes your responses. 
 
1. How soon after you wake up do you smoke your first cigarette? 
______  Within 5 Minutes 
______  Within 6-30 minutes 
______  Within 31-60 minutes 
______  More than 60 minutes 
 
2. Do you find it difficult to refrain from smoking in places where it is forbidden (e.g. in 
church, at the library, at the movies, etc.)? 
______  No 
______  Yes 
 
3. Which cigarette would you hate most to give up? 
______  The first one in the morning 
______  All others 
 
4. How many cigarettes per day do you smoke? 
______  10 or less 
______  11-20 
______  21-30 
______  31 or more 
 
5. Do you smoke more frequently during the first hours after waking than during the rest 
of the day? 
______  No 
______  Yes 
 
6. Do you smoke if you are so ill that you are in bed most of the day? 
______  No 
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______  Yes 
 
University of Rhode Island Stages of Change Assessment (URICA) 
 
Please indicate the extent to which you tend to agree or disagree with each statement. In each 
case, make your choice in terms of how you feel right now, not what you have felt in the past 
or would like to feel.  
 
For all the statements that refer to your “problem”, answer in terms of your smoking. And 
“here” refers to the place of treatment. 
 
There are FIVE possible responses to each of the items in the questionnaire: 
1 = Strongly Disagree   2 = Disagree   3 = Undecided   4 = Agree   5 = Strongly Agree 
 
1. As far as I’m concerned, I don’t have any problems that need 
changing. 
_____ 
2. I think I might be ready for some self-improvement. _____ 
3. I am doing something about the problems that had been bothering 
me. 
_____	
4. It might be worthwhile to work on my problem. _____	
5. I’m not the problem one. It doesn’t make much sense for me to be 
here. 
_____	
6. It worries me that I might slip back on a problem I have already 
changed, so I am here to seek help. 
_____	
7. I am finally doing some work on my problem. _____	
8. I’ve been thinking that I might want to change something about 
myself. 
_____	
9. I have been successful in working on my problem but I’m not sure I 
can keep up the effort on my own. 
_____	
10. At times my problem is difficult, but I’m working on it. _____	
11. Being here is pretty much a waste of time for me because the 
problem doesn’t have to do with me. 
_____	
12. I’m hoping this place will help me to better understand myself. _____	
13. I guess I have faults, but there’s nothing that I really need to change. _____	
14. I am really working hard to change. _____	
15. I have a problem and I really think I should work at it. _____	
16. I’m not following through with what I had already changed as well 
as I had hoped, and I’m here to prevent a relapse of the problem. 
_____	
17. Even though I’m not always successful in changing, I am at least 
working on my problem. 
_____	
18. I thought once I had resolved my problem I would be free of it, but 
sometimes I still find myself struggling with it. 
_____	
19. I wish I had more ideas on how to solve the problem. _____	
20. I have started working on my problems but I would like help. _____	
21. Maybe this place will be able to help me. _____	
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22. I may need a boost right now to help me maintain the changes I’ve 
already made. 
_____	
23. I may be part of the problem, but I don’t really think I am. _____	
24. I hope that someone here will have some good advice for me. _____	
25. Anyone can talk about changing; I’m actually doing something about 
it. 
_____	
26. All this talk about psychology is boring. Why can’t people just forget 
about their problems? 
_____	
27. I’m here to prevent myself from having a relapse of my problem. _____	
28. It is frustrating, but I feel I might be having a recurrence of a 
problem I thought I had resolved. 
_____	
29. I have worries but so does the next guy. Why spend time thinking 
about them? 
_____	
30. I am actively working on my problem. _____	
31. I would rather cope with my faults than try to change them. _____	
32. After all I had done to try to change my problem, every now and 
again it comes back to haunt me. 
_____	
 
Motivation to Stop Smoking (MTSS) 
 
Please indicate which of the following describes you?  
1. "I don't want to stop smoking" 
2. "I think I should stop smoking but don't really want to" 
3. "I want to stop smoking but haven't thought about when" 
4. "I really want to stop smoking but I don't know when I will" 
5. "I want to stop smoking and hope to soon" 
6. "I really want to stop smoking and intend to in the next 3 months" 
7. "I really want to stop smoking and intend to in the next month". 
 
Smoking Self-Efficacy Questionnaire (SEQ-12) 
 
The following are some situations in which certain people might be tempted to smoke. Please 
indicate whether you are sure that you could refrain from smoking in each situation using one 
of the following answers: 
 
1 = Not at all sure  2 = Not very sure 3 = More or less sure 
4 = Fairly sure  5 =Absolutely sure 
 
1. When I feel nervous  _______ 
2. When I feel depressed     _______ 
3. When I am angry      _______ 
4. When I feel very anxious     _______ 
5. When I want to think about a difficult problem  _______ 
6. When I feel the urge to smoke    _______ 
7. When having a drink with friends    _______ 
8. When celebrating something    _______ 
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9. When drinking beer, wine, or other spirits   _______ 
10. When I am with smokers     _______ 
11. After a meal      _______ 
12. When having coffee or tea    _______ 
 
Positive and Negative Affect Schedule (PANAS) 
 
This scale consists of a number of words that describe different feelings and emotions.  Read 
each item and then mark the appropriate answer in the space next to the word.  Indicated what 
extent you feel in this moment, that is, how you currently feel today.  Use the following scale to 
record your answers.  
 
_______________________________________________________________ 
1   2            3   4     5 
very slightly          a little  moderately   quite a bit         extremely 
or not at all 
 
 _____ Interested _____ Irritable 
 
_____ Distressed _____ Alert 
 
_____ Excited _____ Ashamed 
 
_____ Upset _____ Inspired 
 
_____ Strong     _____ Nervous 
 
_____ Guilty    _____ Determined 
 
_____ Scared    _____ Attentive 
 
_____ Hostile    _____ Jittery 
 
_____ Enthusiastic   _____ Active 
 
_____ Proud    _____ Afraid 
 
 
Smoking-related Weight and Eating Episodes Test (SWEET) 
 
_______________________________________________________________ 
     1   2            3   4     5 
Never                   Rarely  Sometimes          Often         Always 
 
 
1. When I feel hungry, I have a cigarette to curb my appetite    _____ 
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2. When I crave unhealthy food, I have a cigarette to avoid eating   _____ 
3. When I feel like having a snack, I have a cigarette instead    _____ 
4. If I don’t smoke soon after a meal, I continue to eat more than I need _____ 
5. Smoking after a meal helps me to avoid overeating     _____ 
6. When I am full, I smoke so that I won’t eat more     _____ 
7. When I feel fat, I have a cigarette       _____ 
8. I smoke when I am worried about gaining weight     _____ 
9. I crave tasty foods when I haven’t smoked in a while    _____ 
10. I feel hungrier when I haven’t smoked in a while     _____ 




Geriatric Depression Scale 
 
Choose the best answer for how you have felt over the past week: 
 




Menopause Rating Scale (MRS) 
 
 Which of the following symptoms apply to you at this time? Please, mark the appropriate box for 
each symptom. For symptoms that do not apply, please mark ‘none’. 
 
 Symptoms: very 
   none mild moderate severe severe 
    I ------------ I-------------I------------- I ------------ I 
  Score    = 0 1 2 3 4 
 
1. Hot flushes, sweating 
(episodes of sweating) .............................................................! ! ! ! ! 
2. Heart discomfort (unusual awareness of heart 
beat, heart skipping, heart racing, tightness)...........................! ! ! ! ! 
3. Sleep problems (difficulty in falling asleep, 
difficulty in sleeping through, waking up early) ........................! ! ! ! ! 
4. Depressive mood (feeling down, sad, on the 
verge of tears, lack of drive, mood swings) .............................! ! ! ! ! 
5. Irritability (feeling nervous, inner tension, 
feeling aggressive) ..................................................................! ! ! ! ! 
6. Anxiety (inner restlessness, feeling panicky)...........................! ! ! ! ! 
7. Physical and mental exhaustion (general decrease 
in performance, impaired memory, decrease in 
concentration, forgetfulness) ...................................................! ! ! ! ! 
8. Sexual problems (change in sexual desire, in 
sexual activity and satisfaction) ...............................................! ! ! ! ! 
9. Bladder problems (difficulty in urinating, 
increased need to urinate, bladder incontinence)....................! ! ! ! ! 
10. Dryness of vagina (sensation of dryness or burning 
in the vagina, difficulty with sexual intercourse) ......................! ! ! ! ! 
11. Joint and muscular discomfort (pain in the joints, 




2. Have you dropped many of your activities and interests? YES / NO 
3. Do you feel that your life is empty? YES / NO  
4. Do you often get bored? YES / NO 
5. Are you in good spirits most of the time? YES / NO 
6. Are you afraid that something bad is going to happen to you? YES / NO 
7. Do you feel happy most of the time? YES / NO 
8. Do you often feel helpless? YES / NO 
9. Do you prefer to stay at home, rather than going out and doing new things? YES / NO 
10. Do you feel you have more problems with memory than most? YES / NO 
11. Do you think it is wonderful to be alive now? YES / NO 
12. Do you feel pretty worthless the way you are now? YES / NO 
13. Do you feel full of energy? YES / NO 
14. Do you feel that your situation is hopeless? YES / NO 
15. Do you think that most people are better off than you are? YES / NO 
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